Name: Patient Derived Xenograft (PDX) Models Market Size, Share, Industry, Forecast and outlook (2023-2030)
Brand: DataM Intelligence
SKU: PH3429
Price: 4350 USD
Availability: InStock

Patient Derived Xenograft Models Market Size, Share & Report 2023-2030

Patient Derived Xenograft (PDX) Models Market Size, Share, Industry, Forecast and outlook (2023-2030)

<h2>Global Patient-Derived Xenograft (PDX) Models Market is segmented&nbsp;&nbsp; By Type (Mice Model, Rats Model, By Tumor Type, Gastrointestinal Tumor Model, Gynecological Tumor Model, Respiratory Tumor Model, Other Tumor Model ), By Application (Preclinical Drug Development, Biomarker Analysis, Basic Cancer Research ), By End-user (Pharmaceutical &amp; Biotechnology Companies, Contract Research Organizations (CROs), Academic &amp; Research Institutions, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) &ndash; Size, Share Outlook, and Opportunity Analysis, 2023-2030</h2>

<h2>&nbsp;</h2>

<h2>Market Overview</h2>

<blockquote>
The global patient derived xenograft (PDX) models market size was valued US$ XX billion in 2022&nbsp;and is estimated to reach US$ XX billion by 2029, growing at a CAGR of XX % during the forecast period (2023-2030).&nbsp;
</blockquote>

Patient-derived xenografts (PDX) are models of cancer where the cells or tissue of a patient&rsquo;s tumor are embedded into an immune-deficient or humanized mouse. PDX models resemble human tumor biology allowing for natural cancer sequence and offering the most translational research model for estimating efficacy.

<h2>Market Dynamics</h2>

The major factors driving the growth of this market are the growing demand for personalized medicine, continuous support for cancer research from the public and private sectors, and growth in the number of R&amp;D activities in the pharmaceutical industry.

The growing demand for personalized medicine will drive the market growth

Personalized medicine is developing tailored medicines to provide individualized medication and care based on individual and genetic variations. These medicines are produced through the use of animal models. In this process, immunodeficient models are revamped with human tissues, and the disease expressed is recorded. It is followed by employing the model with drugs/gene therapeutics to find the most suitable medication, thus generating suitable or personalized medicines.

The development of therapeutics for key disorders such as cancer has attracted significant attention. Presently, cancer is a significant burden on the healthcare sector across the world. As per the data published by GLOBOCAN in 2020, it is expected that 19.3 million cases and 10 million cancer deaths occurred in 2020. In vivo and in vitro strategies are being developed to fight the rising prevalence of cancer and offer efficient treatments to patients. A significant advancement in this regard is the development of PDX models, as they have imminent high power for the efficacy of standard and novel anti-cancer therapeutics. Owing to this convenience, these models are frequently being used in preclinical studies.

&nbsp;

Rising demand for humanized PDX models is driving the market growth

Immunodeficient mice are now reconstituted with bone marrow or peripheral blood cells and patient tumor implants to generate humanized xenograft models. These models present a valuable stage to study the participation of xenogeneic immune cells in the overall anti-tumor immunity. They also help study immunotherapy drugs aimed at mobilizing the effector arm of the immune system. However, in humanized xenografts, there is a potential risk of graft versus host disease. Therefore the limitation can be mitigated by keeping the experimental setup and analysis to a reasonable time frame of 6&ndash;10 weeks.

However, these models are not fitting for evaluating stroma-tumor interactions, majorly accountable for tumor growth and progression in a patient. Humanized PDX models help surmount these issues and are gaining demand in the market.

For instance, in September 2018, JSR Corporation company announced the addition of PDX models of prostate cancer to its product portfolio.

&nbsp;

The high cost of personalized PDX models will hamper the market growth in the forecast period

However, for building the personalized PDX models, a patient&rsquo;s tumor is embedded and grown in various immunocompromised models. It is then stored, fragmented, and inserted again in a more extensive set of models treated with different drugs and drug combinations. After analyzing the cost of building and maintaining these models, coupled with the necessity of expensive drugs in these models, PDX experiments will cost thousands of dollars, even in the case of a particular patient. Moreover, using PDX models in government-funded research can also be cost-prohibitive. These factors are limiting the adoption of PDX models market across the globe.

COVID-19 Impact Analysis

The COVID-19 pandemic has impacted the healthcare systems globally and also has a notable impact on the market. PDX models market is negatively impacted by COVID 19 pandemic due to decreased productivity in life science organizations associated with country-wise lockdowns, the interruption of clinical trials, and decreased pharma R&amp;D deals in therapeutic areas.

For instance, As per the GEP Worldwide, it is estimated that more than 1,200 clinical trials over the globe were interrupted by June 2020. Nearly 61% of clinical trials were disrupted due to the delay of patient enrolment. Trials including respiratory disease, ID/anti-infectives, oncology, and cardiovascular disease were the hard-hit during this time. The market is propelled to grow at a steady rate after the situation gets normal.

<h2>Segment Analysis</h2>

The mice model segment is expected to grow at the fastest CAGR during the forecast period (2021-2028) &nbsp;&nbsp;

The mice model are expected to account for the largest share of the market. Mice models are small animal models for several infectious disorders, including&nbsp; Zika virus, hepatitis B virus (HBV), hepatitis C virus (HCV), and cytomegalovirus (CMV), among others. Therefore certain mice models are widely used for various viral investigations in pre-clinical studies.

For instance, in March 2019, the National Institute of Allergy and Infectious Diseases funded projects to conduct detailed characterization, direct comparisons, and additional humanized immune system (HIS) mouse models. The increasing need to evaluate the outcomes of drugs on humans coupled with a growing focus on analyzing human-specific infections, treatments, and immune responses fosters the development and use of humanized mice models.

&nbsp;Major companies are concentrating on developing their product portfolios by new launches.&nbsp; For instance, in July 2019, Taconic Biosciences launched the first commercially available diet-induced NASH rodent model. This new model will keep researchers months of preparation and expedite the clinical development of NASH therapy to treat liver failure.

Thus, the mice model segment is expanding, increasing R&amp;D activities in the pharmaceutical industry.

Respiratory tumor model segments are expected to dominate the patient-derived xenograft (PDX) models market, by tumor type, during the forecast period&nbsp;&nbsp; 

The respiratory tumor model segment is anticipated to grow at a faster pace in the forecast period. The key constituents contributing to the segment&#39;s growth include increasing research activities in oncology and the increasing focus of market players on generating lung cancer PDX models, and the increasing number of cancer cases.

As per WHO, cancer is the second principal cause of death globally and is accountable for&nbsp; 9.6 million deaths in 2018. Many companies focus on producing breakthrough products to tackle chronic diseases to keep their competitive edge and penetrate new regional markets. Additionally, funding for companies associated with cancer research is anticipated to boost the market.

&nbsp;

<h2>Geographical Analysis</h2>

North America region holds the largest market share in the global Patient-derived xenograft (PDX) models market 

North America region dominates the global patient-derived xenograft (PDX) models market estimated for the largest market share in 2020, owing to a surge in funding and awareness among patients about personalized medication. Patient-derived tumor xenografts are perceived as very suitable preclinical cancer models. According to the American Cancer Society, there were 1,735,350 new cases of cancer diagnosed in the United States in 2018. Also, in 2018, the National Institute of Cancer expands the repository of cancer investigation models to incorporate more research models.

As per the American Cancer Society&#39;s estimation, the new lung cancer cases in the United States for 2018 were around 234,030, and about 154,050 deaths were expected due to lung cancer. In the United States, lung cancer survival has been improved, and the incidence of localized lung cancer has increased.

Market players are involved in product launch, product trials pipelines, product approvals and acquisitions. For instance, In November 2019, Envigo acquired the assets of the research models business unit of Horizon Discovery Group plc

Hence, the North American region is expected to grow faster due to rising preclinical activities by pharmaceutical companies and rising cancer research in this region.

<h2>Competitive Landscape</h2>

The patient-derived xenograft (PDX) models market is moderately competitive with the presence of local as well as global companies. &nbsp;Some of the key players which are contributing to the growth of the market include Charles River Laboratories, Envigo, JSR Corporation (Crown Bioscience Inc.), Champions Oncology, Inc., EPO Berlin-Buch GmbH, Hera BioLabs, Horizon Discovery Group plc, WuXi AppTec, BEIJING IDMO Co. Ltd., Shanghai ChemPartner Co., Ltd. among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the patient-derived xenograft (PDX) models market globally. &nbsp;&nbsp;&nbsp;

<h3>Patient-Derived Xenograft (PDX) Models Market Key Companies to Watch</h3>

Charles River Laboratories

Overview: Charles River Laboratories International, Inc. is an American pharmaceutical company specializing in various preclinical and clinical laboratory, gene therapy and cell therapy services for the Pharmaceutical, Medical Device and Biotechnology industries. It also supplies assorted biomedical products and outsourcing services for research and development in the pharmaceutical industry (for example, contract research organization services) and offers support in basic research, drug discovery, safety and efficacy, clinical support, and manufacturing.

Product Portfolio: The company offers research models &amp; services, discovery services, preclinical CRO services for safety assessment, and laboratory sciences among others.

Key Development: In 2019, Charles River Laboratories renewed its online Tumor Model Compendium by combining 79 new patient-derived xenografts, ten new cell line-derived xenografts, and 36 new cell line models for several cancer types including anal, colon, lung, and renal cancer, as well as leukemia and melanoma.

Why Purchase the Report?

<ul>
	<li>Visualize the composition of the patient-derived xenograft (PDX) models market segmentation by type, tumor type, application and end user highlighting the key commercial assets and players.</li>
	<li>Identify commercial opportunities in the patient-derived xenograft (PDX) models market by analyzing trends and co-development deals.</li>
	<li>Excel data sheet with thousands of data points of patient-derived xenograft (PDX) models market-level 4/5 segmentation.</li>
	<li>PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.</li>
	<li>Product mapping in excel for the key product of all major market players</li>
</ul>

The global patient-derived xenograft (PDX) models market report would provide an access to an approx. 61 market data table, 52 figures and 180 pages. &nbsp;

&nbsp;

Target Audience

<ul>
	<li>Service Providers/ Buyers</li>
	<li>Industry Investors/Investment Bankers</li>
	<li>Education &amp; Research Institutes</li>
	<li>Research Professionals</li>
	<li>Emerging Companies</li>
	<li>Manufacturers</li>
</ul>

<h3 style="background:#eeeeee; border:1px solid #cccccc; padding:5px 10px">Trending Topics</h3>

<a href="https://www.datamintelligence.com/research-report/rnai-therapeutics-market">RNAi Therapeutics Market</a>

<a href="https://www.datamintelligence.com/research-report/chitosan-derivatives-market">Chitosan Derivatives Market</a>

<a href="https://www.datamintelligence.com/research-report/bovine-lactoferrin-market">Bovine Lactoferrin Market</a>

<h2 style="background:#eeeeee; border:1px solid #cccccc; padding:5px 10px">Table of Contents</h2>

<ol>
	<li>
	<h3>Methodology and Scope</h3>

	<ol>
		<li>Research Methodology</li>
		<li>Research Objective and Scope of the Report</li>
	</ol>
	</li>
	<li>
	<h3>Market Definition and Overview</h3>
	</li>
	<li>
	<h3>Executive Summary</h3>

	<ol>
		<li>Market Snippet by Type</li>
		<li>Market Snippet by Tumor Type</li>
		<li>Market Snippet by Application</li>
		<li>Market Snippet by End User</li>
		<li>Market Snippet by Region</li>
	</ol>
	</li>
	<li>
	<h3>Market Dynamics</h3>

	<ol>
		<li>Market Impacting Factors
		<ol>
			<li>Drivers
			<ol>
				<li>The growing demand for personalized medicine will drive the market growth</li>
				<li>Rising demand for humanized PDX models is driving the market growth &nbsp;</li>
			</ol>
			</li>
			<li>Restraints:
			<ol>
				<li>High cost of personalized PDX models will hamper the market growth in the forecast period</li>
			</ol>
			</li>
			<li>Opportunity</li>
			<li>Impact Analysis</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>Industry Analysis
	<ol>
		<li>Porter&#39;s Five Forces Analysis</li>
		<li>Supply Chain Analysis</li>
		<li>Pricing Analysis</li>
		<li>Regulatory Analysis</li>
		<li>Reimbursement Analysis</li>
		<li>Unmet Needs</li>
	</ol>
	</li>
	<li>
	<h3>COVID-19 Analysis</h3>

	<ol>
		<li>Analysis of Covid-19 on the Market
		<ol>
			<li>Before COVID-19 Market Scenario</li>
			<li>Present COVID-19 Market Scenario</li>
			<li>After COVID-19 or Future Scenario</li>
		</ol>
		</li>
		<li>Pricing Dynamics Amid Covid-19</li>
		<li>Demand-Supply Spectrum</li>
		<li>Government Initiatives Related to the Market During Pandemic</li>
		<li>Manufacturers Strategic Initiatives</li>
		<li>Conclusion&nbsp;</li>
	</ol>
	</li>
	<li>
	<h3>By Type</h3>

	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type Segment</li>
			<li>Market Attractiveness Index, By Type Segment</li>
		</ol>
		</li>
		<li>Mice Model*
		<ol>
			<li>Introduction</li>
			<li>Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028</li>
		</ol>
		</li>
		<li>Rats Model</li>
	</ol>
	</li>
	<li>
	<h3>By Tumor Type</h3>

	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Tumor Type</li>
			<li>Market Attractiveness Index, By Tumor Type</li>
		</ol>
		</li>
		<li>Gastrointestinal Tumor Model*
		<ol>
			<li>Introduction</li>
			<li>Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028</li>
		</ol>
		</li>
		<li>Gynecological Tumor Model</li>
		<li>Respiratory Tumor Model</li>
		<li>Other Tumor Model</li>
	</ol>
	</li>
	<li>
	<h3>By Application</h3>

	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application</li>
			<li>Market Attractiveness Index, By Application</li>
		</ol>
		</li>
		<li>Preclinical Drug Development*
		<ol>
			<li>Introduction</li>
			<li>Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028</li>
		</ol>
		</li>
		<li>Biomarker Analysis</li>
		<li>Basic Cancer Research</li>
	</ol>
	</li>
	<li>
	<h3>By End User</h3>

	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User Segment</li>
			<li>Market Attractiveness Index, By End User Segment</li>
		</ol>
		</li>
		<li>Pharmaceutical &amp; Biotechnology Companies *
		<ol>
			<li>Introduction</li>
			<li>Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028</li>
		</ol>
		</li>
		<li>Contract Research Organizations (CROs)</li>
		<li>Academic &amp; Research Institutions</li>
		<li>Others</li>
	</ol>
	</li>
	<li>
	<h3>By Region</h3>

	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028, By Region</li>
			<li>Market Attractiveness Index, By Region</li>
		</ol>
		</li>
		<li>North America
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Tumor Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>U.S.</li>
				<li>Canada</li>
				<li>Mexico</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>Europe
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Tumor Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>Germany</li>
				<li>U.K.</li>
				<li>France</li>
				<li>Italy</li>
				<li>Spain</li>
				<li>Rest of Europe</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>South America
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Tumor Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>Brazil</li>
				<li>Argentina</li>
				<li>Rest of South America</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>Asia Pacific
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Tumor Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>China</li>
				<li>India</li>
				<li>Japan</li>
				<li>Australia</li>
				<li>Rest of Asia Pacific</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>Middle East and Africa
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Tumor Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>
	<h3>Competitive Landscape</h3>

	<ol>
		<li>Key Developments and Strategies</li>
		<li>Company Share Analysis</li>
		<li>Product Benchmarking</li>
		<li>Key Companies to Watch</li>
		<li>Company with disruptive technology</li>
		<li>Start Up Companies</li>
	</ol>
	</li>
	<li>
	<h3>Global Patient Derived Xenograft (PDX) Models Market- Company Profiles</h3>

	<ol>
		<li>Charles River Laboratories*
		<ol>
			<li>Company Overview</li>
			<li>Product Portfolio and Description</li>
			<li>Key Highlights</li>
			<li>Financial Overview</li>
		</ol>
		</li>
		<li>Envigo</li>
		<li>&nbsp;JSR Corporation (Crown Bioscience Inc.)</li>
		<li>&nbsp;Champions Oncology, Inc.</li>
		<li>&nbsp;EPO Berlin-Buch GmbH</li>
		<li>&nbsp;Hera BioLabs</li>
		<li>&nbsp;Horizon Discovery Group plc</li>
		<li>WuXi AppTec</li>
		<li>BEIJING IDMO Co. Ltd.</li>
		<li>Shanghai ChemPartner Co., Ltd..(*LIST NOT EXHAUSTIVE)</li>
	</ol>
	</li>
	<li>
	<h3>DataM Intelligence&nbsp;&nbsp;</h3>

	<ol>
		<li>Appendix</li>
		<li>About Us and Services</li>
		<li>Contact Us</li>
	</ol>
	</li>
</ol>

<h2 style="background:#eeeeee; border:1px solid #cccccc; padding:5px 10px">List of Tables &amp; Figures</h2>

List of Tables

Table 01&nbsp;&nbsp; Global Patient Derived Xenograft (PDX) Models Market Value, By Type, 2021, 2025 &amp; 2029($ Million)

Table 02&nbsp;&nbsp; Global Patient Derived Xenograft (PDX) Models Market Value, By Application, 2021, 2025 &amp; 2029($ Million)

Table 03&nbsp;&nbsp; Global Patient Derived Xenograft (PDX) Models Market Value, By End User, 2021, 2025 &amp; 2029($ Million)

Table 04&nbsp;&nbsp; Global Patient Derived Xenograft (PDX) Models Market Value, By Region, 2021, 2025 &amp; 2029($ Million)

Table 05&nbsp;&nbsp; Global Patient Derived Xenograft (PDX) Models Market Value, By Type, 2021, 2025 &amp; 2029($ Million)

Table 06&nbsp;&nbsp; Global Patient Derived Xenograft (PDX) Models Market Value, By Type, 2018-2029 ($ Million)

Table 07&nbsp;&nbsp; Global Patient Derived Xenograft (PDX) Models Market Value, By Application, 2021, 2025 &amp; 2029($ Million)

Table 08&nbsp; Global Patient Derived Xenograft (PDX) Models Market Value, By Application, 2018-2029 ($ Million)

Table 09&nbsp;&nbsp; Global Patient Derived Xenograft (PDX) Models Market Value, By End User, 2021, 2025 &amp; 2029($ Million)

Table 10&nbsp;&nbsp; Global Patient Derived Xenograft (PDX) Models Market Value, By End User, 2018-2029 ($ Million)

Table 11&nbsp;&nbsp;&nbsp; Global Patient Derived Xenograft (PDX) Models Market Value, By Region, 2021, 2025 &amp; 2029($ Million)

Table 12&nbsp;&nbsp; Global Patient Derived Xenograft (PDX) Models Market Value, By Region, 2018-2029 ($ Million)

Table 13&nbsp;&nbsp; North America Patient Derived Xenograft (PDX) Models Market Value, By Type, 2018-2029 ($ Million)

Table 14&nbsp;&nbsp; North America Patient Derived Xenograft (PDX) Models Market Value, By Application, 2018-2029 ($ Million)

Table 15&nbsp;&nbsp; North America Patient Derived Xenograft (PDX) Models Market Value, By End User, 2018-2029 ($ Million)

Table 16&nbsp;&nbsp; North America Patient Derived Xenograft (PDX) Models Market Value, By Country, 2018-2029 ($ Million)

Table 17&nbsp;&nbsp;&nbsp; South America Patient Derived Xenograft (PDX) Models Market Value, By Type, 2018-2029 ($ Million)

Table 18&nbsp;&nbsp; South America Patient Derived Xenograft (PDX) Models Market Value, By Application, 2018-2029 ($ Million)

Table 19&nbsp;&nbsp; South America Patient Derived Xenograft (PDX) Models Market Value, By End User, 2018-2029 ($ Million)

Table 20&nbsp;&nbsp; South America Patient Derived Xenograft (PDX) Models Market Value, By Country, 2018-2029 ($ Million)

Table 21&nbsp;&nbsp; Europe Patient Derived Xenograft (PDX) Models Market Value, By Type, 2018-2029 ($ Million)

Table 22&nbsp;&nbsp; Europe Patient Derived Xenograft (PDX) Models Market Value, By Application, 2018-2029 ($ Million)

Table 23&nbsp;&nbsp; Europe Patient Derived Xenograft (PDX) Models Market Value, By End User, 2018-2029 ($ Million)

Table 24&nbsp;&nbsp; Europe Patient Derived Xenograft (PDX) Models Market Value, By Country, 2018-2029 ($ Million)

Table 25&nbsp;&nbsp; Asia-Pacific Patient Derived Xenograft (PDX) Models Market Value, By Type, 2018-2029 ($ Million)

Table 26&nbsp;&nbsp; Asia-Pacific Patient Derived Xenograft (PDX) Models Market Value, By Application, 2018-2029 ($ Million)

Table 27&nbsp;&nbsp; Asia-Pacific Patient Derived Xenograft (PDX) Models Market Value, By End User, 2018-2029 ($ Million)

Table 28&nbsp;&nbsp; Asia-Pacific Patient Derived Xenograft (PDX) Models Market Value, By Country, 2018-2029 ($ Million)

Table 29&nbsp;&nbsp; Middle East &amp; Africa Patient Derived Xenograft (PDX) Models Market Value, By Type, 2018-2029 ($ Million)

Table 30&nbsp;&nbsp; Middle East &amp; Africa Patient Derived Xenograft (PDX) Models Market Value, By Application, 2018-2029 ($ Million)

Table 31&nbsp;&nbsp; Middle East &amp; Africa Patient Derived Xenograft (PDX) Models Market Value, By End User, 2018-2029 ($ Million)

Table 32&nbsp;&nbsp; Charles River Laboratories: Overview

Table 33&nbsp;&nbsp; Charles River Laboratories: Product Portfolio

Table 34&nbsp;&nbsp; Charles River Laboratories: Key Developments

Table 35&nbsp;&nbsp; Envigo: Overview

Table 36&nbsp;&nbsp; Envigo: Product Portfolio

Table 37&nbsp;&nbsp; Envigo: Key Developments

Table 38&nbsp;&nbsp; JSR Corporation (Crown Bioscience Inc.): Overview

Table 39&nbsp;&nbsp; JSR Corporation (Crown Bioscience Inc.): Product Portfolio

Table 40&nbsp;&nbsp; JSR Corporation (Crown Bioscience Inc.): Key Developments

Table 41&nbsp;&nbsp; Champions Oncology, Inc.: Overview

Table 42&nbsp;&nbsp; Champions Oncology, Inc.: Product Portfolio

Table 43&nbsp;&nbsp; Champions Oncology, Inc.: Key Developments

Table 44&nbsp;&nbsp; EPO Berlin-Buch GmbH: Overview

Table 45&nbsp;&nbsp; EPO Berlin-Buch GmbH: Product Portfolio

Table 46&nbsp;&nbsp; EPO Berlin-Buch GmbH: Key Developments

Table 47&nbsp;&nbsp; Hera BioLabs: Overview

Table 48&nbsp;&nbsp; Hera BioLabs: Product Portfolio

Table 49&nbsp;&nbsp; Hera BioLabs: Key Developments

Table 50&nbsp;&nbsp; Horizon Discovery Group plc: Overview

Table 51&nbsp;&nbsp; Horizon Discovery Group plc: Product Portfolio

Table 52&nbsp;&nbsp; Horizon Discovery Group plc: Key Developments

Table 53&nbsp;&nbsp; WuXi AppTec: Overview

Table 54&nbsp;&nbsp; WuXi AppTec: Product Portfolio

Table 55&nbsp;&nbsp; WuXi AppTec: Key Developments

Table 56&nbsp;&nbsp; BEIJING IDMO Co. Ltd.: Overview

Table 57&nbsp;&nbsp; BEIJING IDMO Co. Ltd.: Product Portfolio

Table 58&nbsp;&nbsp; BEIJING IDMO Co. Ltd.: Key Developments

Table 59&nbsp;&nbsp; Shanghai ChemPartner Co., Ltd.: Overview

Table 60&nbsp;&nbsp; Shanghai ChemPartner Co., Ltd.: Product Portfolio

Table 61&nbsp;&nbsp; Shanghai ChemPartner Co., Ltd.: Key Developments

List of Figures

Figure 01 Global Patient Derived Xenograft (PDX) Models Market Share, By Type, 2021 &amp; 2029 (%)

Figure 02 Global Patient Derived Xenograft (PDX) Models Market Share, By Application, 2021 &amp; 2029 (%)

Figure 03 Global Patient Derived Xenograft (PDX) Models Market Share, By End User, 2021 &amp; 2029 (%)

Figure 04 Global Patient Derived Xenograft (PDX) Models Market Share, By Region, 2021 &amp; 2029 (%)

Figure 05 Global Patient Derived Xenograft (PDX) Models Market Value, 2018-2029 ($ Million)

Figure 06 Global Patient Derived Xenograft (PDX) Models Market Y-o-Y Growth, By Type, 2021-2029(%)

Figure 07 Mice Model: Global Patient Derived Xenograft (PDX) Models Market Value, 2018-2029 ($ Million)

Figure 08&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rats Model: Global Patient Derived Xenograft (PDX) Models Market Value, 2018-2029 ($ Million)

Figure 09 Global Patient Derived Xenograft (PDX) Models Market Y-o-Y Growth, By Application, 2021-2029(%)

Figure 10 Preclinical Drug Development: Global Patient Derived Xenograft (PDX) Models Market Value, 2018-2029 ($ Million)

Figure 11&nbsp; Biomarker Analysis: Global Patient Derived Xenograft (PDX) Models Market Value, 2018-2029 ($ Million)

Figure 12 Basic Cancer Research: Global Patient Derived Xenograft (PDX) Models Market Value, 2018-2029 ($ Million)

Figure 13 Global Patient Derived Xenograft (PDX) Models Market Y-o-Y Growth, By End User, 2021-2029(%)

Figure 14 Pharmaceutical &amp; Biotechnology Companies: Global Patient Derived Xenograft (PDX) Models Market Value, 2018-2029 ($ Million)

Figure 15 Contract Research Organizations (CROs): Global Patient Derived Xenograft (PDX) Models Market Value, 2018-2029 ($ Million)

Figure 16 Academic &amp; Research Institutions: Global Patient Derived Xenograft (PDX) Models Market Value, 2018-2029 ($ Million)

Figure 17&nbsp; Others: Global Patient Derived Xenograft (PDX) Models Market Value, 2018-2029 ($ Million)

Figure 18 Global Patient Derived Xenograft (PDX) Models Market Y-o-Y Growth, By Region, 2021-2029(%)

Figure 19 North America Patient Derived Xenograft (PDX) Models Market Value, 2018-2029 ($ Million)

Figure 20 North America Patient Derived Xenograft (PDX) Models Market Share, By Type, 2021 &amp; 2029 (%)

Figure 21 North America Patient Derived Xenograft (PDX) Models Market Share, By Application, 2021 &amp; 2029 (%)

Figure 22 North America Patient Derived Xenograft (PDX) Models Market Share, By End User, 2021 &amp; 2029 (%)

Figure 23 North America Patient Derived Xenograft (PDX) Models Market Share, By Country, 2021 &amp; 2029 (%)

Figure 24 South America Patient Derived Xenograft (PDX) Models Market Value, 2018-2029 ($ Million)

Figure 25 South America Patient Derived Xenograft (PDX) Models Market Share, By Type, 2021 &amp; 2029 (%)

Figure 26 South America Patient Derived Xenograft (PDX) Models Market Share, By Application, 2021 &amp; 2029 (%)

Figure 27 South America Patient Derived Xenograft (PDX) Models Market Share, By End User, 2021 &amp; 2029 (%)

Figure 28 South America Patient Derived Xenograft (PDX) Models Market Share, By Country, 2021 &amp; 2029 (%)

Figure 29 Europe Patient Derived Xenograft (PDX) Models Market Value, 2018-2029 ($ Million)

Figure 30 Europe Patient Derived Xenograft (PDX) Models Market Share, By Type, 2021 &amp; 2029 (%)

Figure 31 Europe Patient Derived Xenograft (PDX) Models Market Share, By Application, 2021 &amp; 2029 (%)

Figure 32 Europe Patient Derived Xenograft (PDX) Models Market Share, By End User, 2021 &amp; 2029 (%)

Figure 33 Europe Patient Derived Xenograft (PDX) Models Market Share, By Country, 2021 &amp; 2029 (%)

Figure 34 Asia-Pacific Patient Derived Xenograft (PDX) Models Market Value, 2018-2029 ($ Million)

Figure 35 Asia-Pacific Patient Derived Xenograft (PDX) Models Market Share, By Type, 2021 &amp; 2029 (%)

Figure 36 Asia-Pacific Patient Derived Xenograft (PDX) Models Market Share, By Application, 2021 &amp; 2029 (%)

Figure 37 Asia-Pacific Patient Derived Xenograft (PDX) Models Market Share, By End User, 2021 &amp; 2029 (%)

Figure 38 Asia-Pacific Patient Derived Xenograft (PDX) Models Market Share, By Country, 2021 &amp; 2029 (%)

Figure 39 Middle East &amp; Africa Patient Derived Xenograft (PDX) Models Market Value, 2018-2029 ($ Million)

Figure 40 Middle East &amp; Africa Patient Derived Xenograft (PDX) Models Market Share, By Type, 2021 &amp; 2029 (%)

Figure 41 Middle East &amp; Africa Patient Derived Xenograft (PDX) Models Market Share, By Application, 2021 &amp; 2029 (%)

Figure 42 Middle East &amp; Africa Patient Derived Xenograft (PDX) Models Market Share, By End User, 2021 &amp; 2029 (%)

Figure 43 Charles River Laboratories: Financials

Figure 44 Envigo: Financials

Figure 45 JSR Corporation (Crown Bioscience Inc.): Financials

Figure 46 Champions Oncology, Inc.: Financials

Figure 47 EPO Berlin-Buch GmbH: Financials

Figure 48 Hera BioLabs: Financials

Figure 49 Horizon Discovery Group plc: Financials

Figure 50 WuXi AppTec: Financials

Figure 51 BEIJING IDMO Co. Ltd.: Financials

Figure 52 Shanghai ChemPartner Co., Ltd.: Financials